India's GST collections remained strong, rising to Rs 2.04 lakh crore in September, however experts express concern over the wide gap in ta...

Hospital stocks extended losses for a second session after the Supreme Court questioned steep markups on cancer drugs and raised concerns o...

Sector leader Tata Consultancy Services and its nearest rival, Infosys, are projected to report weak numbers for the three months ending Se...

Linux Laboratories has secured $70 million in equity funding from ChrysCapital and Tata Capital Healthcare Fund III. This investment involv...

Cupid shares surged 7% after entering the Nifty Smallcap 250 index, extending gains to 16% in two sessions. The company has raised FY27 rev...

Foreign portfolio investors have dumped Indian telecom stocks for the eighth consecutive month, pulling out over Rs 32,000 crore in CY26. H...

CoinSwitch achieved profitability based on Adjusted EBITDA for FY26, with revenue growth of 150%. The company's revenue reached Rs 324.19 c...

Anthropic is preparing for a closely watched U.S. IPO after rapid growth in funding, valuation and revenue. The Claude maker faces legal an...

Anupam Rasayan India Limited has finalised its acquisition of a controlling interest in Bliss GVS Pharma, marking a strategic expansion int...

Indian pharma stocks, including Sun Pharma and Aurobindo Pharma, are in focus after the US exempted India and 19 other countries from 100% ...

HRV Pharma CEO Hari Kiran Chereddi says investing in capacity at partner facilities, exploring acquisitions for market access; forecasts Rs...

Jagsonpal Pharmaceuticals has signed a business transfer agreement to acquire the wellness portfolio of Group Pharmaceuticals. The acquisit...

India's pharmaceutical sector is projected to grow at 11-13 percent this fiscal year due to export increases. The domestic market is also e...

The figure underscores the rapid growth of the AI company that shook the tech industry last year after its models challenged US assumptions...

Revenue growth for 18 major Indian states is projected to accelerate to 9–11% in fiscal 2027, taking combined revenues past ₹44 lakh crore,...

HDFC Pharma and Healthcare Fund recorded an impressive 25% return in the last year, surpassing its category average across various time fra...

JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The bro...